Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development

Duane Schulthess, CEO of Vital Transformation, discusses proposed reforms to the Accelerated Approval pathway, the findings of his firms’ analysis, and why these changes could have dire consequences for rare disease drug development.